Tumor-Infiltrating Clonal Hematopoiesis.
Pich O., Bernard E., Zagorulya M., Rowan A., Pospori C., Slama R., Huerga Encabo H., O'Sullivan J., Papazoglou D., Anastasiou P., Iliakis CS., Clark S-A., Dijkstra KK., Barbè V., Bailey C., Stonestrom AJ., Enfield KSS., Green M., Brierley CK., Magness A., Pearce DR., Hynds RE., Zaidi R., Rane JK., Álvarez-Prado ÁF., Thol K., Scott R., Bola SK., Hoxha E., Harris SK., Peggs KS., Quezada SA., Hackshaw A., Zaccaria S., Joyce JA., Malanchi I., Berger MF., Jamal-Hanjani M., Wack A., Downward J., Grey W., Lo Celso C., Grönroos E., Rudin CM., Mead AJ., Bonnet D., Papaemmanuil E., Swanton C.
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear. METHODS: We characterized CHIP and TI-CH in 421 patients with early-stage non-small-cell lung cancer (NSCLC) from the TRACERx study and in 49,351 patients from the MSK-IMPACT pan-cancer cohort. We studied the association of TI-CH with survival and disease recurrence and evaluated the functional effect of TET2-mutant CHIP on the biologic features of lung tumors. RESULTS: Among patients with NSCLC, 42% of those with CHIP had TI-CH. TI-CH independently predicted an increased risk of death or recurrence, with an adjusted hazard ratio of 1.80 (95% confidence interval [CI], 1.23 to 2.63) as compared with the absence of CHIP and an adjusted hazard ratio of 1.62 (95% CI, 1.02 to 2.56) as compared with CHIP in the absence of TI-CH. Among patients with solid tumors, 26% of those with CHIP had TI-CH. TI-CH conferred a risk of death from any cause that was 1.17 times (95% CI, 1.06 to 1.29) as high as the risk with CHIP in the absence of TI-CH. TET2 mutations were the strongest genetic predictor of TI-CH; such mutations enhanced monocyte migration to lung tumor cells, fueled a myeloid-rich tumor microenvironment in mice, and resulted in the promotion of tumor organoid growth. CONCLUSIONS: TI-CH increased the risk of disease recurrence or death among patients with NSCLC and the risk of death from any cause among patients with solid tumors. TI-CH remodeled the tumor immune microenvironment and accelerated tumor organoid growth, findings that support a role for an aging-related hematologic clonal proliferation in cancer evolution. (Funded by the Royal Society and others.).